Exhibit 99.1


FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Second Quarter Results

PROVO, Utah — Aug. 10, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results.

Executive Summary
Q2 2026 vs. Prior-year Quarter

Revenue
    
$320.1 million; (17.1)%
•          (1.0)% FX impact or $(4.0) million
Earnings Per Share (EPS)
    
$(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43
Customers
    
660,037; (14)%
Paid Affiliates
    
120,291; (8)%
Sales Leaders
    
26,998; (9)%
 
“We continue to make progress toward our long-term strategy with the continued rollout of Prysm iO and preparations for the formal launch of India,” said Ryan Napierski, Nu Skin president and CEO. “As these initiatives are taking hold, we are incorporating valuable learnings to strengthen our plans moving forward. At the same time, we are re-aligning our organizational resources to better position the business to drive sustainable, long-term value for our shareholders.”

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 2
Q2 2026 Year-over-year Operating Results

Revenue
    
$320.1 million compared to $386.1 million
•          (1.0)% FX impact or $(4.0) million
Gross Margin
    
68.2% compared to 68.8%
•          Nu Skin business was 77.7% compared to 77.5%
Selling Expenses
    
33.7% compared to 33.2%
•          Nu Skin business was 39.8% compared to 40.0%
G&A Expenses
    
28.4% compared to 27.6%
Operating Margin
    
(18.5)% or 6.1% excluding non-cash impairment charge compared to 8.0%
Interest Expense
    
$3.3 million compared to $2.5 million
Other Income (Expense)
    
$(0.5) million compared to $(0.8) million
Income Tax Rate
    
(295.4)% or 36.6% excluding non-cash tax charge compared to 23.0%
EPS
    
$(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43

Stockholder Value

Dividend Payments
    
$2.9 million
Stock Repurchases
    
$0.0 million
•          $137.3 million remaining in authorization

Q3 and Full-year 2026 Outlook

Q3 2026 Revenue
    
$310 to $340 million; (15)% to (7)%
•          Approximately (3) to (2)% FX impact
Q3 2026 EPS
    
$0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis
2026 Revenue
    
$1.28 to $1.35 billion;  (14)% to (9)%
•          Approximately (1)% FX impact
2026 EPS
    
($4.90) to ($4.73) or $0.70 to $0.90 on an adjusted basis

“We delivered adjusted earnings per share near the midpoint of our guidance, reflecting our ongoing focus on profitability and disciplined execution,” said Chelsea Lantz, interim chief financial officer. “Based on our first-half performance and outlook for the rest of the year, we are updating our annual guidance to revenue of $1.28 billion to $1.35 billion and adjusted earnings per share of $0.70 to $0.90. For the third quarter, we expect revenue between $310 million and $340 million, with adjusted earnings per share in the range of $0.10 to $0.20.”

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 3
Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 24, 2026.
 
About Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
 
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, initiatives, shareholder value, Prysm launch and its timing, and India expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “drive,” “project,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

 •
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

•
economic conditions and events globally;

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 4

•
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;

•
competitive pressures in the company’s markets;

•
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;

•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•
uncertainties regarding the future financial performance of the businesses the company has acquired;

•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and

•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin, and income tax rate, each excluding impairment charges, tax charges, and/or other charges, also are non-GAAP financial measures.

 •
Impairment charges and the tax charge incurred in the second quarter of 2026 are not part of the ongoing operations of our underlying business; and

•
The other charges incurred in connection with certain corporate actions, as described in the footnotes to the non-GAAP reconciliation tables below, are not part of our ongoing operations.

The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 5
The following table sets forth revenue for the three-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

   
Three Months Ended
June 30,
          
Constant-
Currency
Change
  
               
   
2026
    
2025
    
Change
      
Nu Skin
                        
Americas
  
$
59,763
    
$
72,946
      
(18.1
)%
    
(15.8
)%
Mainland China
    
45,956
      
53,224
      
(13.7
)%
    
(18.7
)%
Southeast Asia/Pacific
    
43,257
      
50,834
      
(14.9
)%
    
(16.3
)%
Japan
    
38,143
      
44,550
      
(14.4
)%
    
(5.5
)%
Europe & Africa
    
32,317
      
37,328
      
(13.4
)%
    
(15.2
)%
Hong Kong/Taiwan
    
26,074
      
27,527
      
(5.3
)%
    
(3.6
)%
South Korea
    
25,620
      
34,068
      
(24.8
)%
    
(19.0
)%
Nu Skin Other
    
79
      
427
      
(81.5
)%
    
(81.5
)%
Total Nu Skin
    
271,209
      
320,904
      
(15.5
)%
    
(14.2
)%
Rhyz
                                
Manufacturing
    
46,369
      
60,400
      
(23.2
)%
    
(23.2
)%
Rhyz Other
    
2,534
      
4,834
      
(47.6
)%
    
(47.6
)%
Total Rhyz
    
48,903
      
65,234
      
(25.0
)%
    
(25.0
)%
Total
  
$
320,112
    
$
386,138
      
(17.1
)%
    
(16.1
)%

The following table sets forth revenue for the six-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

   
Six Months Ended
June 30,
          
Constant-
Currency
Change
  
               
   
2026
    
2025
    
Change
      
Nu Skin
                        
Americas
  
$
117,581
    
$
142,004
      
(17.2
)%
    
(14.2
)%
Mainland China
    
91,104
      
100,999
      
(9.8
)%
    
(14.6
)%
Southeast Asia/Pacific
    
88,731
      
103,006
      
(13.9
)%
    
(16.5
)%
Japan
    
77,882
      
87,315
      
(10.8
)%
    
(4.9
)%
Europe & Africa
    
63,535
      
70,349
      
(9.7
)%
    
(15.0
)%
Hong Kong/Taiwan
    
53,531
      
55,974
      
(4.4
)%
    
(4.8
)%
South Korea
    
50,949
      
66,583
      
(23.5
)%
    
(20.2
)%
Nu Skin Other
    
(155
)
    
956
      
(116.2
)%
    
(116.2
)%
Total Nu Skin
    
543,158
      
627,186
      
(13.4
)%
    
(13.4
)%
Rhyz
                                
Manufacturing
    
91,294
      
115,690
      
(21.1
)%
    
(21.1
)%
Rhyz Other
    
6,268
      
7,752
      
(19.1
)%
    
(19.1
)%
Total Rhyz
    
97,562
      
123,442
      
(21.0
)%
    
(21.0
)%
Total
  
$
640,720
    
$
750,628
      
(14.6
)%
    
(14.6
)%

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 6
The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2026 and 2025.

   
Three Months Ended
June 30,
       
Change
  
         
   
2026
    
2025
      
Customers
                  
Americas
    
183,757
      
240,477
      
(24
)%
Mainland China
    
103,891
      
117,325
      
(11
)%
Southeast Asia/Pacific
    
69,354
      
72,814
      
(5
)%
Japan
    
100,849
      
105,961
      
(5
)%
Europe & Africa
    
111,332
      
126,146
      
(12
)%
Hong Kong/Taiwan
    
36,549
      
41,371
      
(12
)%
South Korea
    
54,305
      
67,313
      
(19
)%
Total Customers
    
660,037
      
771,407
      
(14
)%
Paid Affiliates
                        
Americas
    
27,337
      
28,827
      
(5
)%
Mainland China
    
18,736
      
19,399
      
(3
)%
Southeast Asia/Pacific
    
17,677
      
21,092
      
(16
)%
Japan
    
19,018
      
19,605
      
(3
)%
Europe & Africa
    
13,307
      
15,320
      
(13
)%
Hong Kong/Taiwan
    
9,390
      
9,570
      
(2
)%
South Korea
    
14,826
      
16,986
      
(13
)%
Total Paid Affiliates
    
120,291
      
130,799
      
(8
)%
Sales Leaders
                        
Americas
    
5,041
      
5,971
      
(16
)%
Mainland China
    
5,899
      
5,790
      
2
%
Southeast Asia/Pacific
    
3,631
      
4,126
      
(12
)%
Japan
    
5,782
      
5,882
      
(2
)%
Europe & Africa
    
2,216
      
2,695
      
(18
)%
Hong Kong/Taiwan
    
1,858
      
2,063
      
(10
)%
South Korea
    
2,571
      
3,066
      
(16
)%
Total Sales Leaders
    
26,998
      
29,593
      
(9
)%


•
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our salesforce who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

•
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

•
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 7
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

   
Three Months Ended
June 30,
    
Six Months Ended
June 30,
  
         
   
2026
    
2025
    
2026
    
2025
  
Revenue
  
$
320,112
    
$
386,138
    
$
640,720
    
$
750,628
  
Cost of sales
    
101,787
      
120,405
      
207,932
      
237,934
  
Gross profit
    
218,325
      
265,733
      
432,788
      
512,694
  
                                 
Operating expenses:
                                
Selling expenses
    
107,922
      
128,228
      
217,976
      
246,774
  
General and administrative expenses
    
90,847
      
106,725
      
189,391
      
219,929
  
Impairment expenses
    
78,875
      
-
      
80,714
      
25,114
  
Total operating expenses
    
277,644
      
234,953
      
488,081
      
491,817
  
                                 
Operating income (loss)
    
(59,319
)
    
30,780
      
(55,293
)
    
20,877
  
Interest expense
    
3,322
      
2,526
      
7,572
      
5,809
  
Gain on sale of business
    
-
      
-
      
-
      
176,162
  
Other income (expense), net
    
(534
)
    
(843
)
    
2,289
      
(29,218
)
                                 
Income (loss) before provision for income taxes
    
(63,175
)
    
27,411
      
(60,576
)
    
162,012
  
Provision for income taxes
    
186,623
      
6,292
      
187,386
      
33,378
  
                                 
Net income (loss)
  
$
(249,798
)
  
$
21,119
    
$
(247,962
)
  
$
128,634
  
                                 
Net income (loss) per share (Note 7):
                                
Basic
  
$
(5.14
)
  
$
0.43
    
$
(5.12
)
  
$
2.59
  
Diluted
  
$
(5.14
)
  
$
0.43
    
$
(5.12
)
  
$
2.59
  
                                 
Weighted-average common shares outstanding (000s):
                                
Basic
    
48,596
      
49,441
      
48,400
      
49,601
  
Diluted
    
48,596
      
49,499
      
48,400
      
49,748
  

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

   
June 30,
2026
    
December 31,
2025
  
         
ASSETS
            
Current assets:
            
Cash and cash equivalents
  
$
189,643
    
$
238,630
  
Current investments
    
1,743
      
1,211
  
Accounts receivable, net
    
48,902
      
39,544
  
Inventories, net
    
191,497
      
178,643
  
Prepaid expenses and other
    
76,364
      
89,670
  
Total current assets
    
508,149
      
547,698
  
                 
Property and equipment, net
    
379,550
      
377,168
  
Operating lease right-of-use assets
    
65,442
      
74,021
  
Goodwill
    
4,750
      
83,625
  
Other intangible assets, net
    
37,884
      
42,614
  
Other assets
    
125,755
      
280,187
  
Total assets
    
1,121,530
      
1,405,313
  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
                
Current liabilities:
                
Accounts payable
  
$
37,711
    
$
26,183
  
Accrued expenses
    
198,636
      
217,551
  
Current portion of long-term debt
    
20,000
      
20,000
  
Total current liabilities
    
256,347
      
263,734
  
                 
Operating lease liabilities
    
50,075
      
57,640
  
Long-term debt
    
193,664
      
204,187
  
Other liabilities
    
78,705
      
74,512
  
Total liabilities
    
578,791
      
600,073
  
                 
Commitments and contingencies (Notes 6 and 12)
                
                 
Stockholders’ equity:
                
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
    
91
      
91
  
Additional paid-in capital
    
612,412
      
635,994
  
Treasury stock, at cost – 41.9 million and 42.4 million shares
    
(1,558,183
)
    
(1,575,059
)
Accumulated other comprehensive loss
    
(118,152
)
    
(116,105
)
Retained earnings
    
1,606,571
      
1,860,319
  
Total stockholders' equity
    
542,739
      
805,240
  
Total liabilities and stockholders’ equity
  
$
1,121,530
    
$
1,405,313
  

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)

   
Three months ended
June 30,
    
Six months ended
June 30,
  
   
2026
    
2025
    
2026
    
2025
  
Operating Income
  
$
(59,319
)
  
$
30,780
    
$
(55,293
)
  
$
20,877
  
Impact of inventory write-off
    
-
      
-
      
3,116
      
-
  
Impact of other charges(1)
    
-
      
-
      
2,643
      
7,966
  
Impact of impairment
    
78,875
      
-
      
80,714
      
25,114
  
Adjusted operating income
  
$
19,556
    
$
30,780
    
$
31,180
    
$
53,957
  
                                 
                                 
Operating margin
    
(18.5
)%
    
8.0
%
    
(8.6
)%
    
2.8
%
Operating margin, excluding certain charges
    
6.1
%
    
8.0
%
    
4.9
%
    
7.2
%
                                 
Revenue
  
$
320,112
    
$
386,138
    
$
640,720
    
$
750,628
  

(1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 10
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate
(in thousands, except for per share amounts)

   
Three months ended
June 30,
    
Six months ended
June 30,
  
   
2026
    
2025
    
2026
    
2025
  
Provision (benefit) for income taxes
  
$
186,623
    
$
6,292
    
$
187,386
    
$
33,378
  
Impact of inventory write-off on provision for income taxes
    
-
      
-
      
1,065
      
-
  
Impact of other charges(1) on provision for income taxes
    
-
      
-
      
903
      
725
  
Impact of impairment on provision for income taxes
    
(13,370
)
    
-
      
(12,741
)
    
5,433
  
Impact of gain on Mavely sale on provision for income taxes
    
-
      
-
      
-
      
(31,104
)
Impact of gain on unrealized investment loss on provision for income taxes
    
-
      
-
      
-
      
6,074
  
Impact of valuation allowance on deferred tax assets
    
(167,505
)
    
-
      
(167,505
)
    
-
  
Provision for income taxes, excluding impact of certain charges
  
$
5,748
    
$
6,292
    
$
9,108
    
$
14,506
  
                                 
Income before provision for income taxes
    
(63,175
)
    
27,411
      
(60,576
)
    
162,012
  
Impact of inventory write-off
    
-
      
-
      
3,116
      
-
  
Impact of other charges(1)
    
-
      
-
      
2,643
      
7,966
  
Impact of impairment expense:
    
78,875
      
-
      
80,714
      
25,114
  
Impact of gain on Mavely sale
    
-
      
-
      
-
      
(176,162
)
Impact of unrealized investment loss
    
-
      
-
      
-
      
28,077
  
Income before provision for income taxes, excluding impact certain charges
  
$
15,700
    
$
27,411
    
$
25,897
    
$
47,007
  
                                 
Effective tax rate
    
(295.4
)%
    
23.0
%
    
(309.3
)%
    
20.6
%
Effective tax rate, excluding impact of certain charges
    
36.6
%
    
23.0
%
    
35.2
%
    
30.9
%

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 11
NU SKIN ENTERPRISES, INC. 
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)

   
Three months ended
June 30,
    
Six months ended
June 30,
  
   
2026
    
2025
    
2026
    
2025
  
Net income
  
$
(249,798
)
  
$
21,119
    
$
(247,962
)
  
$
128,634
  
Impact of Inventory write-off
                                
Inventory write-off
    
-
      
-
      
3,116
      
-
  
Tax impact
    
-
      
-
      
(1,065
)
    
-
  
Impact of other charges
                                
Other charges
    
-
      
-
      
2,643
      
7,966
  
Tax impact
    
-
      
-
      
(903
)
    
(725
)
Impact of impairment
                                
Impairment charges
    
78,875
      
-
      
80,714
      
25,114
  
Tax impact
    
13,370
      
-
      
12,741
      
(5,433
)
Impact of Mavely sale
                                
Mavely sale
    
-
      
-
      
-
      
(176,162
)
Tax impact
    
-
      
-
      
-
      
31,104
  
Impact of unrealized investment loss
                                
Unrealized investment loss
    
-
      
-
      
-
      
28,077
  
Tax impact
    
-
      
-
      
-
      
(6,074
)
Impact of valuation allowance on deferred tax assets
    
167,505
      
-
      
167,505
      
-
  
Adjusted net income
  
$
9,952
    
$
21,119
    
$
16,789
    
$
32,501
  
                                 
                                 
Diluted earnings per share
  
$
(5.14
)
  
$
0.43
    
$
(5.12
)
  
$
2.59
  
Diluted earnings per share, excluding impact of certain charges
  
$
0.20
    
$
0.43
    
$
0.35
    
$
0.65
  
                                 
Weighted-average common shares outstanding (000)
    
48,596
      
49,499
      
48,400
      
49,748
  

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results
page 12
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

   
Three months ended
September 30, 2026
    
Year ended December 31, 2026
  
   
Low end
    
High end
    
Low end
    
High end
  
Earnings Per Share
  
$
0.00
    
$
0.09
    
$
(4.90
)
  
$
(4.73
)
Impact of inventory write-off
                                
Inventory write-off
    
-
      
-
      
0.06
      
0.06
  
Tax impact
    
-
      
-
      
(0.02
)
    
(0.02
)
Impact of other charges
                                
Other charges(2)
    
0.10
      
0.10
      
0.15
      
0.15
  
Tax impact
    
(0.02
)
    
(0.02
)
    
(0.04
)
    
(0.04
)
Impact of impairment:
                                
Impairment charges
    
-
      
-
      
1.67
      
1.67
  
Tax impact
    
-
      
-
      
0.26
      
0.26
  
Impact of valuation allowance on deferred tax assets
    
0.02
      
0.03
      
3.52
      
3.55
  
Adjusted EPS
  
$
0.10
    
$
0.20
    
$
0.70
    
$
0.90
  

(2) We are currently anticipating other charges for the third quarter of 2026 of approximately $5 million in cash-based transition cost. Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges.

# # #

CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577